Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)

American Heart Journal

Volumn 138, Issue 1 I, 1999, Pages 78-86

  O'Connor, C M ^a   Gattis, W A ^a   Uretsky, B F ^a   Adams K F , Jr ^a   McNulty, S E ^a   Grossman, S H ^a   McKenna, W J ^a   Zannad, F ^a   Swedberg, K ^a   Gheorghiade, M ^a   Califf, R M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE;

ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032814621     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70250-4     Document Type: Article

References (21)

1. Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980;100:622-30.
2. Unverferth DV, Magorien RD, Altschuld R, Kolibash AJ, Lewis R, Leier CV. The hemodynamic and metabolic advantages gained by three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1983;106:29-33.
3. Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB. Sustained improvement in cardiac function in patients with congestive heart failure after short-term infusions of dobutamine. Circulation 1984;69:113-9.
4. Lewin RF, Davidson E, Zafir N, Strasberg B, Sclarovsky S, Hellman C, et al. Short and long term dobutamine treatment in chronic ischemic heart failure. Clin Cardiol 1987;10:335-9.
5. Van den Brande P, Mieghem WV, Demedts M. Intermittent dobutamine infusion in severe chronic heart failure in elderly patients. Gerontology 1990;36:49-54.
6. Miller LW, Merkle EJ, Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 1990;18:S30-S33.
7. Erlemeier HH, Kupper W, Bleifeld W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure: long term effects and lack of tolerance. Cardiovasc Drugs Ther 1992;6:391-8.
8. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996;132:805-8.
9. Maskin CS, Forman R, Sonnenblick EH, Frishman WH, LeJemtel TH. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. Am J Cardiol 1983;51:177-82.
10. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986;112:787-91.
11. Dawson JR, Canepa-Anson R, Kuan P, et al. Symptoms, haemodynamics, and exercise capacity during long-term treatment of chronic heart failure: experience with pirbuterol. Br Heart J 1983;50:282-9.
12. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation 1986;74(suppl II):II-39.
13. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997;349:971-7.
14. Cody RJ, Packer M, Colucci WS. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? J Am Coll Cardiol 1988;12:559-69.
15. Califf RM, Adams KF, McKenna W, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
16. Francis G, Benedict C, Johnstone D, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-30.
17. Benedict CR, Weiner DH, Johnstone DE, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry. J Am Coll Cardiol 1993;22(Suppl A):146A-53A.
18. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
19. Gottlieb SS, Kukin ML, Ahem D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
20. Swedberg K, Eneroth P, Kjekshus J, Wilhelmson L for the CONSENSUS II trial study group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
21. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.